Financhill
Sell
41

IGMS Quote, Financials, Valuation and Earnings

Last price:
$1.27
Seasonality move :
-10.54%
Day range:
$1.29 - $1.40
52-week range:
$0.92 - $22.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
30.60x
P/B ratio:
116.27x
Volume:
367.9K
Avg. volume:
180.3K
1-year change:
-82.51%
Market cap:
$81.2M
Revenue:
$2.7M
EPS (TTM):
-$3.27

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
IGMS
IGM Biosciences
$4.3M -$0.45 -100% -45.57% $1.94
ATNM
Actinium Pharmaceuticals
-- -$0.28 -100% -7.24% $5.00
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$1.56 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
IGMS
IGM Biosciences
$1.35 $1.94 $81.2M -- $0.00 0% 30.60x
ATNM
Actinium Pharmaceuticals
$1.77 $5.00 $55.2M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.60 $0.85 $3.5M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.53 -- $24.6M -- $0.00 0% --
OGEN
Oragenics
$4.51 $1.00 $3.2M -- $0.00 0% 1.44x
TOVX
Theriva Biologics
$0.50 $7.00 $4.1M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
IGMS
IGM Biosciences
-- -0.977 -- 5.39x
ATNM
Actinium Pharmaceuticals
-- -3.250 -- 9.03x
NBY
NovaBay Pharmaceuticals
4.54% -0.941 1.51% 0.75x
NNVC
Nanoviricides
-- -0.642 -- --
OGEN
Oragenics
-- -1.150 -- --
TOVX
Theriva Biologics
-- -3.651 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
IGMS
IGM Biosciences
-- -$32.9M -241.68% -241.68% -6590.58% -$32.6M
ATNM
Actinium Pharmaceuticals
-- -$16.6M -95.08% -95.08% -12769.14% -$7.6M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
NNVC
Nanoviricides
-- -$2.2M -- -- -- -$2M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

IGM Biosciences vs. Competitors

  • Which has Higher Returns IGMS or ATNM?

    Actinium Pharmaceuticals has a net margin of -10599.6% compared to IGM Biosciences's net margin of -11511.11%. IGM Biosciences's return on equity of -241.68% beat Actinium Pharmaceuticals's return on equity of -95.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    IGMS
    IGM Biosciences
    -- -$0.86 $698K
    ATNM
    Actinium Pharmaceuticals
    -- -$0.51 $36.4M
  • What do Analysts Say About IGMS or ATNM?

    IGM Biosciences has a consensus price target of $1.94, signalling upside risk potential of 43.52%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 182.49%. Given that Actinium Pharmaceuticals has higher upside potential than IGM Biosciences, analysts believe Actinium Pharmaceuticals is more attractive than IGM Biosciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    IGMS
    IGM Biosciences
    0 4 0
    ATNM
    Actinium Pharmaceuticals
    2 1 0
  • Is IGMS or ATNM More Risky?

    IGM Biosciences has a beta of 0.525, which suggesting that the stock is 47.463% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.271, suggesting its less volatile than the S&P 500 by 127.061%.

  • Which is a Better Dividend Stock IGMS or ATNM?

    IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IGMS or ATNM?

    IGM Biosciences quarterly revenues are $499K, which are larger than Actinium Pharmaceuticals quarterly revenues of $81K. IGM Biosciences's net income of -$52.9M is lower than Actinium Pharmaceuticals's net income of -$15.9M. Notably, IGM Biosciences's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 30.60x versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IGMS
    IGM Biosciences
    30.60x -- $499K -$52.9M
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$15.9M
  • Which has Higher Returns IGMS or NBY?

    NovaBay Pharmaceuticals has a net margin of -10599.6% compared to IGM Biosciences's net margin of -49.65%. IGM Biosciences's return on equity of -241.68% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    IGMS
    IGM Biosciences
    -- -$0.86 $698K
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About IGMS or NBY?

    IGM Biosciences has a consensus price target of $1.94, signalling upside risk potential of 43.52%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 42.59%. Given that IGM Biosciences has higher upside potential than NovaBay Pharmaceuticals, analysts believe IGM Biosciences is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    IGMS
    IGM Biosciences
    0 4 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is IGMS or NBY More Risky?

    IGM Biosciences has a beta of 0.525, which suggesting that the stock is 47.463% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

  • Which is a Better Dividend Stock IGMS or NBY?

    IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IGMS or NBY?

    IGM Biosciences quarterly revenues are $499K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. IGM Biosciences's net income of -$52.9M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, IGM Biosciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 30.60x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IGMS
    IGM Biosciences
    30.60x -- $499K -$52.9M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns IGMS or NNVC?

    Nanoviricides has a net margin of -10599.6% compared to IGM Biosciences's net margin of --. IGM Biosciences's return on equity of -241.68% beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IGMS
    IGM Biosciences
    -- -$0.86 $698K
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About IGMS or NNVC?

    IGM Biosciences has a consensus price target of $1.94, signalling upside risk potential of 43.52%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 324.84%. Given that Nanoviricides has higher upside potential than IGM Biosciences, analysts believe Nanoviricides is more attractive than IGM Biosciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    IGMS
    IGM Biosciences
    0 4 0
    NNVC
    Nanoviricides
    0 0 0
  • Is IGMS or NNVC More Risky?

    IGM Biosciences has a beta of 0.525, which suggesting that the stock is 47.463% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.749%.

  • Which is a Better Dividend Stock IGMS or NNVC?

    IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IGMS or NNVC?

    IGM Biosciences quarterly revenues are $499K, which are larger than Nanoviricides quarterly revenues of --. IGM Biosciences's net income of -$52.9M is lower than Nanoviricides's net income of -$2.2M. Notably, IGM Biosciences's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 30.60x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IGMS
    IGM Biosciences
    30.60x -- $499K -$52.9M
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
  • Which has Higher Returns IGMS or OGEN?

    Oragenics has a net margin of -10599.6% compared to IGM Biosciences's net margin of --. IGM Biosciences's return on equity of -241.68% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IGMS
    IGM Biosciences
    -- -$0.86 $698K
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About IGMS or OGEN?

    IGM Biosciences has a consensus price target of $1.94, signalling upside risk potential of 43.52%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 565.26%. Given that Oragenics has higher upside potential than IGM Biosciences, analysts believe Oragenics is more attractive than IGM Biosciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    IGMS
    IGM Biosciences
    0 4 0
    OGEN
    Oragenics
    0 1 0
  • Is IGMS or OGEN More Risky?

    IGM Biosciences has a beta of 0.525, which suggesting that the stock is 47.463% less volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.

  • Which is a Better Dividend Stock IGMS or OGEN?

    IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IGMS or OGEN?

    IGM Biosciences quarterly revenues are $499K, which are larger than Oragenics quarterly revenues of --. IGM Biosciences's net income of -$52.9M is lower than Oragenics's net income of -$2.2M. Notably, IGM Biosciences's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 30.60x versus 1.44x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IGMS
    IGM Biosciences
    30.60x -- $499K -$52.9M
    OGEN
    Oragenics
    1.44x -- -- -$2.2M
  • Which has Higher Returns IGMS or TOVX?

    Theriva Biologics has a net margin of -10599.6% compared to IGM Biosciences's net margin of --. IGM Biosciences's return on equity of -241.68% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IGMS
    IGM Biosciences
    -- -$0.86 $698K
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About IGMS or TOVX?

    IGM Biosciences has a consensus price target of $1.94, signalling upside risk potential of 43.52%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1314.14%. Given that Theriva Biologics has higher upside potential than IGM Biosciences, analysts believe Theriva Biologics is more attractive than IGM Biosciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    IGMS
    IGM Biosciences
    0 4 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is IGMS or TOVX More Risky?

    IGM Biosciences has a beta of 0.525, which suggesting that the stock is 47.463% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.

  • Which is a Better Dividend Stock IGMS or TOVX?

    IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IGMS or TOVX?

    IGM Biosciences quarterly revenues are $499K, which are larger than Theriva Biologics quarterly revenues of --. IGM Biosciences's net income of -$52.9M is lower than Theriva Biologics's net income of -$4.3M. Notably, IGM Biosciences's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 30.60x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IGMS
    IGM Biosciences
    30.60x -- $499K -$52.9M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Planet Labs’ Stock Go Next?
Where Will Planet Labs’ Stock Go Next?

On 4 June 2025 Planet reported Q1 FY 2026 revenue of $66.3 million, up 10% year over…

Where Will VICI Properties Be in 5 Years?
Where Will VICI Properties Be in 5 Years?

VICI Properties (NYSE:VICI) is a real estate investment trust focused…

Where Will Exxon Stock Be in 5 Years?
Where Will Exxon Stock Be in 5 Years?

For sure Exxon Mobil (NYSE: XOM) is no hyped-up AI…

Stock Ideas

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 49x

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Sell
43
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
75
INSM alert for Jun 11

Insmed [INSM] is up 7.75% over the past day.

Sell
25
AAON alert for Jun 11

AAON [AAON] is down 3.49% over the past day.

Buy
58
EXOD alert for Jun 11

Exodus Movement [EXOD] is down 8.21% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock